Butchertown Clinical Trials and The Eye Care Institute Announce Our 14th FDA Approval Tyrvaya™

October 19, 2021

For Immediate Release

Oyster Point Pharma, a Princeton, NJ company, has announced the FDA has approved Tyrvaya™ as the first and only nasal spray approved for treating signs and symptoms of Dry Eye Disease.

Guruprasad R. Pattar, MD, PhD, of The Eye Care Institute and Butchertown Clinical Trials, was a principal investigator for the clinical trials leading to the FDA approval of this new treatment option for persons suffering from dry eye disease. Dr. Pattar stated, “this nasal spray gave many of our patients increased comfort during clinical trials here at our facility. The nasal spray will be available soon and it is to be used twice per day per nostril. It is the only approved nasal spray for both signs and symptoms of dry eye disease and is right for many persons who suffer from dry eye disease but find that using eye drops is challenging.”

Jeffrey Nau, Ph.D., MMS, president and CEO of Oyster Point Pharma, commented, “The approval of TYRVAYA Nasal Spray marks a milestone for patients and eye care professionals by providing a new drug treatment option for the signs and symptoms of dry eye disease with a differentiated route of administration that is believed to leverage a nerve pathway that can be accessed within the nose.” This is the 14th FDA-approved drug or device for Louisville, KY-based Butchertown Clinical Trials; the 13th FDA approval was announced just one day ago.

Delivering eye medication by nasal spray is a novel way to help improve the lives of persons who cannot easily use eye drops. This spray is expected to be available during November 2021, by prescription only, packaged in a carton with two nasal spray bottles, each containing a 15-day supply.